GlassScriptPhysician profile
Stephen Anthony Ruhlman
NPI 1679599567
$31,688.07
in general payments reported to CMS, 2019-2025
52 companies · $3,323 in 2025
The $3,323 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,980 · 2020: $8,942 · 2021: $4,443 · 2022: $3,129 · 2023: $3,340 · 2024: $3,530 · 2025: $3,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,959 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,958.95 |
| Education | $235.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,539.74 | 2019-2025 | |
| Gilead Sciences, INC. | $5,376.57 | 2019-2020 | |
| Abbvie INC. | $4,655.38 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $2,737.37 | 2019-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $2,602.79 | 2019-2023 | Krystexxa |
| Amgen INC. | $2,160.31 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Janssen Biotech, INC. | $1,422.45 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $1,351.23 | 2019-2025 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $1,073.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $974.59 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $742.59 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $557.06 | 2022-2025 | Saphnelo, Evusheld |
| Merck Sharp & Dohme LLC | $401.58 | 2019-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.86 | 2019-2025 | Cyltezo, Ofev |
| Sandoz INC. | $166.74 | 2023-2025 | Hyrimoz |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ruhlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.